Littérature scientifique sur le sujet « WASp, pDCs, Type-I-IFN, autoimmunity »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « WASp, pDCs, Type-I-IFN, autoimmunity ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "WASp, pDCs, Type-I-IFN, autoimmunity"
Prete, Francesca, Marco Catucci, Mayrel Labrada, Stefania Gobessi, Maria Carmina Castiello, Elisa Bonomi, Alessandro Aiuti et al. « Wiskott-Aldrich syndrome protein–mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells ». Journal of Experimental Medicine 210, no 2 (21 janvier 2013) : 355–74. http://dx.doi.org/10.1084/jem.20120363.
Texte intégralSchmitt, Heike, Sabrina Sell, Julia Koch, Martina Seefried, Sophia Sonnewald, Christoph Daniel, Thomas H. Winkler et Lars Nitschke. « Siglec-H protects from virus-triggered severe systemic autoimmunity ». Journal of Experimental Medicine 213, no 8 (4 juillet 2016) : 1627–44. http://dx.doi.org/10.1084/jem.20160189.
Texte intégralKarnell, Jodi L., Yanping Wu, Nanette Mittereder, Michael A. Smith, Michele Gunsior, Li Yan, Kerry A. Casey et al. « Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus ». Science Translational Medicine 13, no 595 (26 mai 2021) : eabf8442. http://dx.doi.org/10.1126/scitranslmed.abf8442.
Texte intégralCao, Wei, Jeremy Di Domizio, Stephanie Dorta-Estramera, Mihai Gagea, Ping Li, Liqi Bi et Michel Gilliet. « Nucleic acid-containing amyloid fibrils potently induce Type I interferon and stimulate systemic autoimmunity (P4075) ». Journal of Immunology 190, no 1_Supplement (1 mai 2013) : 127.9. http://dx.doi.org/10.4049/jimmunol.190.supp.127.9.
Texte intégralBarrat, Franck J., et Lishan Su. « A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection ». Journal of Experimental Medicine 216, no 9 (16 août 2019) : 1974–85. http://dx.doi.org/10.1084/jem.20181359.
Texte intégralLorant, Alina K., et Adam Lacy-Hulbert. « Integrin αvβ3 limits TLR signaling in plasmacytoid dendritic cells to prevent autoimmunity. » Journal of Immunology 206, no 1_Supplement (1 mai 2021) : 60.09. http://dx.doi.org/10.4049/jimmunol.206.supp.60.09.
Texte intégralBencze, Dóra, Tünde Fekete et Kitti Pázmándi. « Type I Interferon Production of Plasmacytoid Dendritic Cells under Control ». International Journal of Molecular Sciences 22, no 8 (18 avril 2021) : 4190. http://dx.doi.org/10.3390/ijms22084190.
Texte intégralLorant, Alina K., et Adam Lacy-Hulbert. « Integrin αv limits TLR signaling in plasmacytoid dendritic cells ». Journal of Immunology 204, no 1_Supplement (1 mai 2020) : 226.3. http://dx.doi.org/10.4049/jimmunol.204.supp.226.3.
Texte intégralLande, Roberto, Anna Mennella, Raffaella Palazzo, Immacolata Pietraforte, Katia Stefanantoni, Nicoletta Iannace, Alessia Butera et al. « Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature ». International Journal of Molecular Sciences 21, no 14 (19 juillet 2020) : 5102. http://dx.doi.org/10.3390/ijms21145102.
Texte intégralBabcock, Rachel Lauren, Haiyan S. Li, Yifan Zhou, Taylor T. Chrisikos et Stephanie S. Watowich. « Regulation of Id2 gene expression in plasmacytoid dendritic cells ». Journal of Immunology 204, no 1_Supplement (1 mai 2020) : 229.3. http://dx.doi.org/10.4049/jimmunol.204.supp.229.3.
Texte intégralThèses sur le sujet "WASp, pDCs, Type-I-IFN, autoimmunity"
Prete, Francesca. « The role of Wiskott-Aldrich Syndrome protein-mediated actin dynamics in controlling type-I IFN production in plasmacytoid dendritic cells ». Doctoral thesis, Università degli studi di Trieste, 2012. http://hdl.handle.net/10077/7867.
Texte intégralWiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency characterized by recurrent infections, and a marked predisposition to develop autoimmune phenomena. The disease is caused by mutations in WASp, a key regulator of actin polymerization expressed only in hematopoietic cells. A general impairment of hematopoietic cell functions contributes to the pathogenesis of the disease. Neutrophils, B cells, T cells and DCs deficient for WASp were all shown to have impaired homing ability, a cellular function that strictly depends on spatio-temporal regulation of actin polymerization. WASp null T cells present severe impairment in coupling TCR stimulation to proliferation and fail to organize signaling molecules within the immunological synapse (Badour et al., 2004; Dupre et al., 2002; Sims et al., 2007). B cells intrinsic defects include altered B cell receptor clustering, defective homeostasis of mature B cells and a specific reduction in the expression of the complement receptor (Park et al., 2005; Simon et al., 1992; Westerberg et al., 2001). WASp null DCs fail to assemble podosomes and display late migration from the periphery to lymph nodes (de Noronha et al., 2005). Moreover, WASp expression in DCs is critical to organize the dynamic cytoskeletal changes that facilitate DC-T cell interaction during antigen presentation (Pulecio et al., 2008; Bouma et al., 2011). Together, these cellular alterations provided clues to understand the reduced response to pathogens and the immunodeficiency of WAS patients. However, the mechanisms by which perturbation of actin dynamics promote autoimmune phenomena are less clear. Autoimmune complications occur in 40-72% of children with severe WAS phenotype. The most common autoimmune features that develop in WAS patients include hemolytic anemia, vasculitis, renal disease, and arthritis (Dupuis-Girod et al., 2003; Sullivan et al., 1994; Humblet-baron et al., 2007). Impairment of T and B cell tolerance have been reported in WAS patients and in Was-/- mice, but the exact cellular mechanisms that link loss of WASp function to autoimmunity have not been fully elucidated yet (Becker-Herman et al., 2011; Recher et al., 2012; Marangoni et al., 2007; Maillard et al., 2007; Humblet-Baron et al., 2007). It is increasingly recognized that excessive activation of pDCs and elevated type-I interferon (IFN) levels are pathogenic in several human autoimmune diseases such as SLE, psoriasis, Sjogren’s syndrome. Since WAS autoimmune manifestations partially overlap with those of type-I IFN diseases, we hypothesized that pDCs/IFN-α axis may have a role in WAS-associated autoimmunity. In the first part of results we present the analysis of the pDC compartment in a mouse model of the disease, a mouse knock-out for WASp (WKO mice). We show that pDCs from WKO animals are chronically activated, secrete type-I IFN constitutively and become refractory to further stimulation in vivo. By depleting WASp expression or by interfering with actin dynamics in pDCs we prove that WASp-mediated actin dynamics control the activation of the TLR9/IFN-α pathway in a cell autonomous fashion. Based on the results of previous section, we speculated that WASp may regulate IFN-α production by controlling the correct organization of the endocytic pathway. It is well known, in fact, that type-I IFN production relies on spatio-temporal regulation of TLR9 signaling in the endocytic pathway, at the same time, it is largely established that many steps of the endocytosis are regulated by actin regulatory proteins of the WASp family. Therefore, we proceed presenting a series of experiments exploring the role of WASp in mediating signaling downstream TLR9 activation in pDCs. Tracking of TLR9 agonist in pDCs show that WASp controls cellular architecture and early endosomes size leading to accumulation of large aggregates of TLR9 agonist in WASp-deficient cells. To demonstrate a link between the alteration in the pDCs/IFN-α axis found in WKO mice and the pathogenesis of WAS autoimmunity, we first analyzed the presence in patients of clinical aspects known to be associated with type-I IFN diseases. We report that WAS patients display a moderate type-I interferon signature, indicating an exposure to elevated levels of this cytokine. Finally, we moved back to the mouse model of WAS to start investigating the presence of alterations of innate/adaptive immunity classically attributed to unrestrained type-I IFN production. In line with the well known inducing effects of systemic type-I IFNs, our preliminary data illustrate a generally more activated phenotype of immunocytes in WKO mice. In sum, our work provide 1) the first demonstration of an altered pDCs/IFN-α axis in WAS, 2) the existence of a cell intrinsic mechanism of increased pDCs activation in WASp-null pDC, and 3) a new role for actin in restraining excessive activation of TLR9 in pDCs. These observations add a new layer of complexity to our understanding of the pathophysiology of WAS, and raise important considerations about the treatment of patients with autoimmune phenomena.
XXIV Ciclo
1983